Full Press Release Details
update on fda priority review of dupixent dupilumab for the treatment of copd patients with type 2 inflammation.
REGN
update on fda priority review of dupixent dupilumab for the treatment of copd patients with type 2 inflammation
Key Takeaway: update on fda priority review of dupixent dupilumab for the treatment of copd patients with type 2 inflammation